Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer

Nicola E. Annels, David Mansfield, Mehreen Arif, Carmen Ballesteros-Merino, Guy R. Simpson, Mick Denyer, Sarbjinder S. Sandhu, Alan A. Melcher, Kevin J. Harrington, Bronwyn Davies, Gough Au, Mark Grose, Izhar Bagwan, Bernard Fox, Richard Vile, Hugh Mostafid, Darren Shafren, Hardev S. Pandha

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences